💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for ACADIA Pharmaceuticals Inc. (ACAD)
« Back to company indexACAD Chatter Timeline
Stock Ticker for ACAD
Most Active Tweeters for ACAD
| User | Tweets |
|---|---|
| @ForTheRecord01 | 20 |
| @Tickeron | 6 |
| @Estimize | 4 |
| @Soudesu9 | 4 |
| @TradeWithAlerts | 4 |
Recent Tweets for ACAD
 |
@SeekingAlpha $ACAD - ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2021 Results - Earnings Call Transcript.… https://t.co/nt0BYp6LdP 4:08am |
 |
@drbeckler Hmm, buying on the dip? $ACAD 2:08am |
 |
@bearcapital1 CNS companies need to come up with more unique approaches then just making patients tired. $ACAD ? 1:08am |
|
@bearcapital1 $ACAD at 3.3B I think is meh and no opinion on $FGEN at 1.2B but does it really cost 4.5B to walk away with these f… https://t.co/SOr63Y3GYg 1:08am |
 |
@newsfilterio ACADIA Pharma slides after 2021 guidance lagged expectations $ACAD https://t.co/AN6mE1sxbD 12:08am |
 |
@Soudesu9 $acad put a fork in it August 4th 2021, 10:08pm |
 |
@saltadogato Goodman getting right to the point $ACAD https://t.co/mUSkvWGpML August 4th 2021, 10:08pm |
 |
@ForTheRecord01 $ACAD On today's call, not one analyst asked the execs about appealing the Psych Division's decision (and stall tac… https://t.co/PctquCGmrG August 4th 2021, 10:08pm |
|
@ForTheRecord01 17 months have passed since $ACAD held its pre-sNDA meeting with the FDA. You'd never know so much time has been l… https://t.co/WLgCKvKoAk August 4th 2021, 10:08pm |
 |
@Briefingcom $ACAD: ACADIA Pharmaceuticals beats by $0.03, misses on revs; guides FY21 revs below consensus https://t.co/8WkpBiiWRT August 4th 2021, 10:08pm |
|
@ForTheRecord01 $ACAD If the FDA had any concerns about the efficacy of pimanvaserin in dementia-related psychosis, why didn't the… https://t.co/0e1ZB2A8Gu August 4th 2021, 9:08pm |
 |
@ethanFlare $ACAD - ACADIA Pharma slides after 2021 guidance lagged expectations Cap size: mid, Float 73.3%, Short Interest 6.8… https://t.co/xpuHrhzAIv August 4th 2021, 9:08pm |
 |
@mehabecapital (Earnings) ACADIA ( $ACAD ) Actual.EPS=-0.27 vs Est.EPS=-0.3044, Actual.Rev=115.2M vs Est.Rev=124.9M, Last Quote: $… https://t.co/ywymW921Be August 4th 2021, 8:08pm |
 |
@mediasentiment $ACAD new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 1158 August 4th 2021, 8:08pm |
|
@mediasentiment $ACAD new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 1156 August 4th 2021, 8:08pm |
|
@Soudesu9 $acad sell the company for $25 a share August 4th 2021, 8:08pm |
 |
@Estimize This afternoon's winner for $ACAD is Needham_45 who beats 6 other analysts and the Wall Street Consensus - https://t.co/dbf26mYZgT August 4th 2021, 8:08pm |
|
@Estimize $ACAD beats the Estimize EPS Consensus by 3c and misses the Estimize Revenue Consensus by $10.14M. Reports FQ2 earn… https://t.co/IRzHycZd4f August 4th 2021, 8:08pm |
|
@Estimize $ACAD reports FQ2 earnings of -27c EPS and $115.22M Revs - https://t.co/SRP81Hso2i August 4th 2021, 8:08pm |
|
@ForTheRecord01 Is $ACAD even aware that the acting FDA commissioner has called for an investigation of her own agency? https://t.co/Zi5TAo2okQ August 4th 2021, 8:08pm |
|
@mehabecapital $ACAD @ 21.05 - ACADIA Pharma EPS beats by $0.03, misses on revenue; FY21 guidance lowered https://t.co/tvfpBWLohq August 4th 2021, 8:08pm |
|
@ForTheRecord01 If $ACAD cared about its shareholders at all, it would appeal the recent FDA decision immediately. Nuplazid should… https://t.co/OJu3oUvJA7 August 4th 2021, 8:08pm |
|
@ForTheRecord01 In a staggering show of generosity, the FDA told $ACAD it is willing to reconsider its opinion on the DRP sNDA "som… https://t.co/EGaQotLMoM August 4th 2021, 8:08pm |
|
@ethanFlare $ACAD - ACADIA Pharma EPS beats by $0.03, misses on revenue; FY21 guidance lowered Cap size: mid, Float 73.3%, Shor… https://t.co/F3stQhUgvJ August 4th 2021, 8:08pm |
 |
@fintel_io Also, if you are new to $ACAD here's a background article on Finpedia for you https://t.co/Chy0RZypJd August 4th 2021, 8:08pm |
 |
@DoctorSPAC $ACAD - bad print. August 4th 2021, 8:08pm |
 |
@FlashAlert_me $ACAD [15s. delayed, acc.~90%, always check] Earnings Release August 04, 16:05:00: Q2: GAAP EPS of -$0.27, Revenue… https://t.co/mFHfaeeLZP August 4th 2021, 8:08pm |
|
@FlashAlert_me $ACAD [15s. delayed]: Issued Press Release on August 04, 16:05:00: Acadia Pharmaceuticals Reports Second Quarter 20… https://t.co/Gc5gaZ7UnT August 4th 2021, 8:08pm |
 |
@Sports_bios $ACAD type A mtg - FDA repeats the same stance on subgrp DRP - but they are open to yet another mtg - /// gee.. August 4th 2021, 8:08pm |
 |
@bthefirsttoknow $ACAD: Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results //First out https://t.co/y6SUk6bJqP August 4th 2021, 8:08pm |
 |
@StockPods $ACAD Earnings Call Today: 4:30 PM EST Webcast: https://t.co/wHggeEt5h9 Signup for the StockPods BETA now: https://t.co/Vma4E2hQ99 August 4th 2021, 6:08pm |
 |
@EPSGUID Options are priced for bigger-than-average #earnings move for $ACAD reporting after close via @eWhispers #volatility https://t.co/I0UQKwthar August 4th 2021, 6:08pm |
 |
@piqueing Who else is keenly waiting for the $ACAD news today? August 4th 2021, 6:08pm |
|
@Estimize $ACAD reports after the close, Estimize Consensus +0 EPS and +0.46M Revs compared to WS - https://t.co/dEPtNEgtVM August 4th 2021, 3:08pm |
 |
@TipRanks $ACAD ACADIA: The Street’s Gaze Turns to FDA Meeting’s Outcome on DRP Treatment https://t.co/BMfv7wrLyp August 3rd 2021, 11:08pm |
 |
@MarketCurrents $ACAD - ACADIA Pharma Q2 2021 Earnings Preview https://t.co/PnCPzNamh6 August 3rd 2021, 9:08pm |
 |
@Tickeron Acadia Pharmaceuticals Inc to report earnings on August 04, 2021. Earnings per share (EPS) estimate: $-0.30 $ACAD… https://t.co/yX4kjjRoyk August 3rd 2021, 7:08pm |
 |
@ChartMill $ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.14%. https://t.co/KWWNp7ypOe https://t.co/eBa25Fx2en August 3rd 2021, 3:08pm |
|
@mehabecapital $ACAD in Double Bottom formation , quote @ 20.83 https://t.co/x8qLKHeVOK August 3rd 2021, 2:08pm |
|
@Soudesu9 $acad no news is bad news August 3rd 2021, 1:08pm |
 |
@Adrian97707834 Disapointed because of losses? What doesn't kill you makes you stronger! BUYSIGN001 has no emotions trading $ACAD,… https://t.co/aLlviLY0cA August 3rd 2021, 11:08am |
|
@Adrian97707834 Don't forget your loss-cuts! BUYSIGN001 delivers performance trading $ACAD through consistent loss-cuts execution.… https://t.co/QUPfYkL3EC August 3rd 2021, 11:08am |
|
@Soudesu9 $acad wtf…not a lot of confidence going into earnings August 2nd 2021, 6:08pm |
 |
@tradersreport RT @Tickeron: $ACAD's 10-day Moving Average crossed below its 50-day Moving Average on July 19, 2021. View odds for this and other indicato… August 2nd 2021, 5:08pm |
|
@Tickeron $ACAD's 10-day Moving Average crossed below its 50-day Moving Average on July 19, 2021. View odds for this and othe… https://t.co/3fBHTo2ryB August 2nd 2021, 5:08pm |
 |
@ShortAlgoTrades $ACAD Awaiting buy signal ! https://t.co/PMTRKxMDqn August 2nd 2021, 4:08pm |
 |
@ShortAlgoKing $ACAD Awaiting buy signal ! https://t.co/Vc6u8iCdOL August 2nd 2021, 4:08pm |
|
@saltadogato So $ACAD is likely giving us an update on their type A meeting on Wednesday - given how the stock has been trading,… https://t.co/Qxror0ERNW August 2nd 2021, 3:08pm |
 |
@Gambiste1 RT @Sports_bios: $ACAD much like the SRPT case, the top Q people will ask is - any update from the type A mtg w/ FDA post CRL w/ DRP - what… August 2nd 2021, 2:08pm |
|
@Sports_bios $ACAD much like the SRPT case, the top Q people will ask is - any update from the type A mtg w/ FDA post CRL w/ DRP… https://t.co/xHk1wHWqgz August 2nd 2021, 1:08pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?